Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Comparison of clinical-pathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a Canadian breast screening program: a nested case-control study.

Rayson D, Payne JI, Abdolell M, Barnes PJ, MacIntosh RF, Foley T, Younis T, Burns A, Caines J.

Clin Breast Cancer. 2011 Mar;11(1):27-32. doi: 10.3816/CBC.2011.n.005.

PMID:
21421519
2.

Phenotypic characterization and risk factors for interval breast cancers in a population-based breast cancer screening program in Barcelona, Spain.

Domingo L, Sala M, Servitja S, Corominas JM, Ferrer F, Martínez J, Macià F, Quintana MJ, Albanell J, Castells X.

Cancer Causes Control. 2010 Aug;21(8):1155-64. doi: 10.1007/s10552-010-9541-6.

PMID:
20349271
3.

Human epidermal growth factor receptor 2 status and interval breast cancer in a population-based cancer registry study.

Musolino A, Michiara M, Conti GM, Boggiani D, Zatelli M, Palleschi D, Bella MA, Sgargi P, Di Blasio B, Ardizzoni A.

J Clin Oncol. 2012 Jul 1;30(19):2362-8. doi: 10.1200/JCO.2011.37.6434.

PMID:
22585698
4.

Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers.

Ibrahim E, Al-Gahmi AM, Zeenelin AA, Zekri JM, Elkhodary TR, Gaballa HE, Fawzy EE, El sayed ME, Alzahrani MS.

Med Oncol. 2009;26(3):372-8. doi: 10.1007/s12032-008-9131-6.

PMID:
19034706
5.

Aggressiveness features and outcomes of true interval cancers: comparison between screen-detected and symptom-detected cancers.

Domingo L, Blanch J, Servitja S, Corominas JM, Murta-Nascimento C, Rueda A, Redondo M, Castells X, Sala M.

Eur J Cancer Prev. 2013 Jan;22(1):21-8. doi: 10.1097/CEJ.0b013e328354d324.

PMID:
22584215
6.

Biologic characteristics of interval and screen-detected breast cancers.

Gilliland FD, Joste N, Stauber PM, Hunt WC, Rosenberg R, Redlich G, Key CR.

J Natl Cancer Inst. 2000 May 3;92(9):743-9.

7.

Tumor phenotype and breast density in distinct categories of interval cancer: results of population-based mammography screening in Spain.

Domingo L, Salas D, Zubizarreta R, Baré M, Sarriugarte G, Barata T, Ibáñez J, Blanch J, Puig-Vives M, Fernández A, Castells X, Sala M; INCA Study Group..

Breast Cancer Res. 2014 Jan 10;16(1):R3. doi: 10.1186/bcr3595.

8.

Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program.

Kirsh VA, Chiarelli AM, Edwards SA, O'Malley FP, Shumak RS, Yaffe MJ, Boyd NF.

J Natl Cancer Inst. 2011 Jun 22;103(12):942-50. doi: 10.1093/jnci/djr138.

9.

The role of mammography screening attendance and detection mode in predicting breast cancer survival-is there added prognostic value?

Biesheuvel C, Czene K, Orgeás CC, Hall P.

Cancer Epidemiol. 2011 Dec;35(6):545-50. doi: 10.1016/j.canep.2011.02.008.

PMID:
21470933
10.
12.

Multicentric mammary carcinoma: evidence of monoclonal proliferation.

Middleton LP, Vlastos G, Mirza NQ, Eva S, Sahin AA.

Cancer. 2002 Apr 1;94(7):1910-6.

13.

Ten years of breast screening in the Nova Scotia Breast Screening Program, 1991-2001. experience: use of an adaptable stereotactic device in the diagnosis of screening-detected abnormalities.

Caines JS, Schaller GH, Iles SE, Woods ER, Barnes PJ, Johnson AJ, Jones GR, Borgaonkar JN, Rowe JA, Topp TJ, Porter GA.

Can Assoc Radiol J. 2005 Apr;56(2):82-93.

PMID:
15957275
14.

Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.

Schwentner L, Wolters R, Koretz K, Wischnewsky MB, Kreienberg R, Rottscholl R, Wöckel A.

Breast Cancer Res Treat. 2012 Apr;132(3):1073-80. doi: 10.1007/s10549-011-1935-y.

PMID:
22205141
15.

The consequence of undertreating breast cancer in the elderly.

Gajdos C, Tartter PI, Bleiweiss IJ, Lopchinsky RA, Bernstein JL.

J Am Coll Surg. 2001 Jun;192(6):698-707.

PMID:
11400963
16.

Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer.

Ejlertsen B, Jensen MB, Rank F, Rasmussen BB, Christiansen P, Kroman N, Kvistgaard ME, Overgaard M, Toftdahl DB, Mouridsen HT; Danish Breast Cancer Cooperative Group..

J Natl Cancer Inst. 2009 May 20;101(10):729-35. doi: 10.1093/jnci/djp090.

19.

Impact of screening and risk factors for local recurrence and survival after conservative surgery and radiotherapy for early breast cancer: results from a large series with long-term follow-up.

Kunkler IH, Kerr GR, Thomas JS, Jack WJ, Bartlett JM, Pedersen HC, Cameron DA, Dixon JM, Chetty U; Edinburgh Breast Group..

Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):829-38. doi: 10.1016/j.ijrobp.2011.08.018.

PMID:
22197227
20.

Lymphovascular invasion is associated with reduced locoregional control and survival in women with node-negative breast cancer treated with mastectomy and systemic therapy.

Truong PT, Yong CM, Abnousi F, Lee J, Kader HA, Hayashi A, Olivotto IA.

J Am Coll Surg. 2005 Jun;200(6):912-21.

PMID:
15922205
Items per page

Supplemental Content

Support Center